Fig. 3From: Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort studyFVC changes in autoantibody-positive patients in relation to pirfenidone treatment. FVC declined in patients who were never treated with pirfenidone more than in those treated with pirfenidone (p = 0.031). FVC forced vital capacityBack to article page